Kiniksa files Form 144 for Class A share sales

Kiniksa Pharmaceuticals, Ltd. Form 144 notice lists proposed sales of Class A ordinary shares tied to equity compensation and a restricted stock lapse.

Accepted by SEC EDGAR 04/09/2026 - 04:03 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals, Ltd. Form 144 notice lists proposed sales of Class A ordinary shares tied to equity compensation and a restricted stock lapse. The excerpt shows a 04/07/2026 restricted-stock lapse and a proposed sale quantity listed as 79,513.00, plus a recent reported sale of 114,989.00 shares on 04/06/2026.

Key Figures

Proposed sale quantity: 79,513.00 shares Reported sale in past 3 months: 114,989.00 shares Restricted stock lapse date: 04/07/2026 +1 more

4 metrics

Proposed sale quantity 79,513.00 shares listed under Securities To Be Sold, 04/07/2026

Reported sale in past 3 months 114,989.00 shares Securities Sold During The Past 3 Months, 04/06/2026

Restricted stock lapse date 04/07/2026 Event labeled 'Restricted Stock Lapse' in excerpt

Exchange listing noted NASDAQ Securities Information line referencing exchange

Key Terms

Form 144, Restricted Stock Lapse, Equity Compensation

3 terms

Form 144 regulatory

"144: Securities To Be Sold"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock Lapse financial

"Class A ordinary shares | 04/07/2026 | Restricted Stock Lapse"

Equity Compensation financial

"04/07/2026 | Equity Compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does KNSA's Form 144 disclose?

The filing discloses proposed sales of Class A ordinary shares associated with equity compensation and a restricted stock lapse dated 04/07/2026. It lists a proposed quantity of 79,513.00 and a reported sale of 114,989.00 on 04/06/2026.

Who is the selling party named in the Form 144 for KNSA?

The excerpt names an individual address for Ross Moat in London and identifies transactions tied to Kiniksa Pharmaceuticals International, plc. The filing links the sales to equity compensation and a restricted stock lapse.

What dates are shown on the KNSA Form 144 excerpt?

Key dates in the excerpt are a restricted stock lapse and securities-to-be-sold entry dated 04/07/2026 and a NASDAQ-related entry dated 04/09/2026. A reported sale is dated 04/06/2026.

How many shares are listed in the KNSA excerpt?

The excerpt shows a proposed sale quantity of 79,513.00 shares and a recent sale amount of 114,989.00 shares. These figures appear in the securities and "sold during the past 3 months" sections.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001857177
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Kiniksa Pharmaceuticals International, plc
SEC File Number	001-38492
Address of Issuer	105 PICCADILLY, SECOND FLOOR LONDON UNITED KINGDOM W1J 7NJ
Phone	7814319100
Name of Person for Whose Account the Securities are To Be Sold	Moat Ross
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A ordinary shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	1703	79513.00	45900637	04/09/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A ordinary shares	04/07/2026	Restricted Stock Lapse	Kiniksa Pharmaceuticals, Ltd.			1703	04/07/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Ross Moat 105 PICCADILLY, SECOND FLOOR LONDON X0 W1J 7NJ	Kiniksa Pharmaceuticals International, plc	04/06/2026	2367	114989.00

144: Remarks and Signature

Remarks
Date of Notice	04/09/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	11/13/2024
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Ross Moat
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)